17th week of 2010 patent applcation highlights part 47 |
Patent application number | Title | Published |
20100105597 | METHODS FOR MAKING A NIL-PHOSPHATE LIQUID AUTOMATIC DISHWASHING COMPOSITION - A method of making a liquid ADW detergent composition comprising the successive steps of: a) forming a solution premix comprising: i) water; ii) an alkali metal carbonate; iii) a dispersant polymer; and b) adding an alkali metal silicate to said solution premix wherein said composition comprises a low-foaming nonionic surfactant and wherein said composition is substantially free of a phosphate builder. | 2010-04-29 |
20100105598 | Non-Phosphate Dish Detergents - The present invention provides non-phosphate containing dishwashing detergent compositions. The present invention also provides methods for the production of and use of such detergents. | 2010-04-29 |
20100105599 | SUBTILISIN VARIANTS - New subtilisin homologues (both nucleic acids and proteins) are provided. Compositions which include these new proteins, recombinant cells, shuffling methods involving the new homologues, antibodies to the new homologues, and methods of using the homologues are also provided. | 2010-04-29 |
20100105600 | Detergent or Cleaning Agent Comprising Polysaccharide - The invention describes a stable and transparent liquid washing agent or liquid cleaning agent having a graying-inhibiting polysaccharide that has a particle size smaller than 100 nm. The invention also relates to the use of the liquid washing agent or liquid cleaning agent, and to a method for the manufacture thereof. | 2010-04-29 |
20100105601 | METHOD FOR TREATING A SYNUCLEINOPATHY - The present invention relates to methods for restoring fast axonal transport in a cell which expresses a pathological synuclein protein and for treating a synucleinopathy using a Protein Kinase C mu or Src-Family Tyrosine Kinase inhibitor. | 2010-04-29 |
20100105602 | TREATMENT OF INTRACELLULAR BACTERIAL INFECTIONS - The present invention relates to methods for treating intracellular bacterial infections with defensin polypeptides. | 2010-04-29 |
20100105603 | Methods and Preparations For Curing Clinically Ill Patients - This invention relates to a life saving medicament for critically ill patients and a method of treatment. The composition is a pharmaceutically effective amount of a blood glucose regulator which is used to control the blood glucose level. | 2010-04-29 |
20100105604 | ALLYLOXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS - The present invention relates to pharmaceutical compounds for delivering active agents, such as biologically or chemically active agents, to a target. The invention also relates to pharmaceutical compositions comprising at least one delivery agent compound of the present invention and at least one active agent, and unit dosage forms comprising such compositions. Methods for the preparation and administration of the pharmaceutical compositions are also disclosed. | 2010-04-29 |
20100105605 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF - Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. | 2010-04-29 |
20100105606 | METHODS FOR MAKING HIGH OXYGEN AFFINITY MODIFIED HEMOGLOBIN FOR OXYGEN TRANSPORT - The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to autooxidation and superior oxygen carrying characteristics. | 2010-04-29 |
20100105607 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS - Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of the a glycopeptide (Compound A, Compound B, Compound H or Compound C) or the monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; conversion of the amide group in amino acid-3 on these scaffolds to various acylamide, acylsulfonamide, acylsulfonylurea derivatives; aminomethylation with substituent containing sulfonamide or acylsulfonamide group on amino acid-7 through Mannich reaction; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Also provided are methods for the synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections. | 2010-04-29 |
20100105608 | Peptides and methods using same for diagnosis and treatment of amyloid-associated disease - Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases. | 2010-04-29 |
20100105609 | Processes for Preparing Eptifibatide - The present invention provides, inter alia, convergent processes for preparing eptifibatide that involve coupling a 2-6 eptifibatide fragment to an activated cysteinamide residue to form a 2-7 eptifibatide fragment, attaching a mercaptopropionic acid residue to the 2-7 eptifibatide fragment through disulfide bond formation, coupling the peptide intramolecularly, and removing the protecting group, to form eptifibatide. The invention further provides products produced by the described processes, novel compounds that can be used as synthetic intermediates for the preparation of eptifibatide, and novel compounds that are structurally similar to eptifibatide. | 2010-04-29 |
20100105610 | Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells - The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and prevent tumor formation and progression and to inhibit tumor cell aggressiveness. The invention further provides methods of inhibiting tumor cell growth and/or treating aggressive tumors in a mammal comprising administering to the mammal, having at least one tumor cell present in its body, an effective amount of an inhibitor of Nodal activity. | 2010-04-29 |
20100105611 | METHOD OF TREATING RESPIRATORY DISORDERS - The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of respiratory disorders. | 2010-04-29 |
20100105612 | AGENT CONTAINING FUSED PROTEIN OF SOLUBLE RANKL WITH EPITOPE TAG - The present invention provides a reagent containing a fused protein of RANKL with an epitope tag that has improved effects of differentiating and activating osteoclasts and improved preservation stability compared with the case of using RANKL alone, and an agent for differentiating and activating osteoclasts that can be used in vitro or in vivo, containing, as an active ingredient, a fused protein of soluble RANKL with an epitope tag peptide. | 2010-04-29 |
20100105613 | THERAPEUTIC AGENT FOR OCCLUSIVE PERIPHERAL VASCULAR DISEASE, AND USE THEREOF - A study was made on the therapeutic effect of midkine on an occlusive peripheral vascular disease, and it was found that midkine has an activity of promoting neovascularization and that a blood vessel can be proliferated and the blood flow in the upper and lower limbs can be improved (in other words, the condition of an ischemic disease in the upper and lower limbs can be ameliorated) by introducing midkine into a site affected by the occlusive peripheral vascular disease. | 2010-04-29 |
20100105614 | ULTRA LOW DOSE DOXEPIN AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to doxepin, pharmaceutically acceptable salts and prodrugs of doxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders. | 2010-04-29 |
20100105615 | Nutritional Composition To Promote Healthy Development And Growth - A nutritional composition for improving the immunological function of a subject, including a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; and about 0.1 to about 1 mg/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide which has a fermentation rate which is demonstrably slower than that of galacto-oligosaccharide. | 2010-04-29 |
20100105616 | POLYETHYLENE GLYCOL-G-CSF CONJUGATE - The present invention relates to three-branched PEG-G-CSF conjugate of general formula (1) in which the bonding ratio of three-branched polyethylene glycol (PEG) and G-CSF is 1:1 (mol/mol), wherein PEG has an average molecular weight of from 200 to 45,000 daltons; a pharmaceutical composition comprising the same, and a preparing method thereof. | 2010-04-29 |
20100105617 | C-Terminal Attachment of Two Chemical Groups to Peptides - The present invention relates to a method for C-terminal attachment of two property-modifying groups to a peptide. | 2010-04-29 |
20100105618 | Non-Natural Recombinant Gelatins with Enhanced Functionality - The invention concerns recombinant gelatin monomers and recombinant gelatins comprising or consisting of multimers of the monomers. The recombinant gelatins can be produced with enhanced stability. | 2010-04-29 |
20100105619 | CYSTEINE-CONTAINING PEPTIDES HAVING ANTIOXIDANT PROPERTIES - Cysteine containing amphipathic alpha helices of the exchangeable apolipoproteins, as exemplified by apolipoprotein (apo) A-I | 2010-04-29 |
20100105620 | Polypeptides that bind Trail-R1 and Trail-R2 - Agonists for TRAIL death receptors including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds to at least one of TRAIL death receptors TRAIL-R1 and TRAIL-R2. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce apoptosis in pathogenic cells expressing a TRAIL death receptor. Pharmaceutical compositions are described for treating diseases associated with cells expressing DR4 and DR5, such as tumor cells. Methods for selecting polypeptides and preparing multimeric complexes. | 2010-04-29 |
20100105621 | Therapies for acute renal failure - The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein/bone morphogenetic protein (OP/BMP) family within the TGF-β superfamily of proteins. | 2010-04-29 |
20100105622 | Protein Product for Treatment of Infectious Diseases and Related Inflammatory Processes - The inventors have found that CD6, a member of the Scavenger Receptor Cysteine-Rich (SRSR) superfamily expressed on human lymphocytes binds to Gram-positive and Gram-negative bacteria, as well as to other microbial structures. Thus, a CD6 product is useful for the manufacture of a medicament for therapeutic and/or preventive treatment of an infectious disease or of an inflammatory condition related to an infectious disease or to the presence of a product derived from an infectious agent in a mammal including a human. Examples of such inflammatory conditions are systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock. | 2010-04-29 |
20100105623 | SCHIZOPHRENIA-RELATED ISOFORM OF KCNH2 AND DEVELOPMENT OF ANTIPSYCHOTIC DRUGS - The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia. | 2010-04-29 |
20100105624 | CALCITONIN DRUG-OLIGOMER CONJUGATES, AND USES THEREOF - Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed. | 2010-04-29 |
20100105625 | Product and Methods for Diagnosis and Therapy for Cardiac and Skeletal Muscle Disorders - Disclosed are products and methods to promote myoblast activation and cardiac and skeletal muscle growth or regeneration, and to treat heart and skeletal muscle diseases, based on the identification of cellular processes affected by prelamin A processing. | 2010-04-29 |
20100105626 | Novel Analogues of Antimicrobial and Anticancer Peptide Synthesized and Produced from Gaegurin 5 - The present invention is related to antimicrobial and anticancer peptide engineering using Gaegurin 5 isolated from Korean frog ( | 2010-04-29 |
20100105627 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY - The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. | 2010-04-29 |
20100105628 | REDUCING POST-OPERATIVE ADHESION FORMATION WITH INTRAPERITONEAL GLUTAMINE - Glutamine source formulations that have release profiles that provide for sustained release via intraperitoneal administration of glutamine reduces post-operative adhesion formation. | 2010-04-29 |
20100105629 | N-Substituted Peptidomimetic Inhibitors of Dipeptidylpeptidase IV - One aspect of the present invention relates to inhibitors of post-pro line protease enzymes, such as inhibitors of dipeptidyl peptidase IV (DPIV). Other aspects of the invention relate to pharmaceutical compositions and methods of use thereof. In certain embodiments, a DPIV inhibitor comprises a carboxylic acid-containing side chain moiety at the P1 or P2 position or both. The inhibitors of the invention should possess improved specificity for the targeted protease and low toxicity. | 2010-04-29 |
20100105630 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS - Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders. | 2010-04-29 |
20100105631 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence - Inositol derivatives are described that are represented by the structural formula I | 2010-04-29 |
20100105632 | Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals - The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof. | 2010-04-29 |
20100105633 | PROCESS - The invention relates to a process for the preparation of water-soluble chitosan salts, to chitosan products produced by this process and to their uses, e.g. in pharmaceutical or veterinary compositions or as a food or cosmetic additive. More specifically, the invention relates to a process for preparing a water-soluble chitosan salt which comprises: (a) contacting a solid chitosan with at least one protic acid whereby to produce a water-soluble chitosan salt; and (b) optionally recovering said salt, wherein said chitosan is converted into said salt whilst remaining substantially in the solid state. Gaseous or liquid protic acids may be used, including hydrochloric, acetic and propionic acids. | 2010-04-29 |
20100105634 | USE OF GLUCOSAMINE AS A MENTAL AND PHYSICAL STRESS RECOVERY ENHANCER AND A PERFORMANCE ENHANCER - The present invention provides a composition comprising glucosamine salts or derivatives for rapid enhancement of at least one of mental performance and physical performance of a subject. The composition enhances the mental performance and physical performance by reducing at least one kind of cellular stress effects in the body of the subject. In one embodiment mental performance is enhanced by improving memory recall of the subject. The composition according to an embodiment of the present invention is an ingestion product. | 2010-04-29 |
20100105635 | COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASE ASSOCIATED WITH AMYLOIDOSIS THROUGH INHIBITION OF AMYLOID PROTEIN AGGREGATION AND PROMOTION OF AMYLOID PROTEIN DEGRADATION - It is an object of the present invention to provide a means for promoting amyloid protein degradation and a means for inhibiting amyloid protein aggregation. | 2010-04-29 |
20100105636 | T-TYPE CALCIUM CHANNEL BLOCKER - There is provided a T-type calcium channel blocker that is a compound of formula (1), a pharmaceutically acceptable salt thereof or a solvate thereof: | 2010-04-29 |
20100105637 | Drug-surfactant complexes for sustained release - The invention involves sustained-release pharmaceutical compositions containing a water-soluble ionic small molecule pharmaceutical agent complexed with an oppositely charged surfactant, particularly a natural bile surfactant. The complexes are sustained-release ionic complexes. The complexes release the ionic pharmaceutical agents into aqueous solution slowly and with zero-order kinetics. Thus, they can be formulated into sustained-release pharmaceutical compositions. | 2010-04-29 |
20100105638 | COSMETIC COMPOSITIONS - The present invention relates to the use of ascorbyl phosphate and niacinamide to suppress the crystallization of biotin in cosmetic or dermatological compositions. Furthermore, the invention relates to cosmetic or dermatological compositions comprising ascorbyl phosphate, niacinamide, biotin and a cosmetically acceptable carrier. | 2010-04-29 |
20100105639 | MESALAMINE SUPPOSITORY - The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m | 2010-04-29 |
20100105640 | Aromatase Inhibitors for Emergency Contraception - There is disclosed an emergency contraceptive preparation which comprises at least one aromatase inhibitor wherein the preparation comprises at least one dose for administration on one or more days to a female patient following an unprotected sexual encounter until the establishment or continuation of pregnancy of the patient is prevented. Also disclosed is a method of emergency contraception. | 2010-04-29 |
20100105641 | Oral Contraceptive Spray - The subject invention provides a liquid contraceptive formulation for oral transmucosal administration. The formulation comprises etonogestrel, optionally together with ethinyl estradiol but does not contain a matrix former or a percutaneous absorption promoter, which is a hydroxy acid or a salt thereof. | 2010-04-29 |
20100105642 | NOVEL COMPOUNDS 409 - The present invention provides a compound of formula (I) | 2010-04-29 |
20100105643 | Ophthalmic composition - It has now been found that tetrahydrocortisol alone, when in solution or in the form of nanoparticles, or a combination of compounds where each affects intraocular pressure by a different mechanism of action is especially valuable for the treatment of elevated intraocular pressure and glaucoma, especially in the resistant patient. With such a combination, each compound may be present at a reduced concentration, even to a sub-therapeutic level (i.e., as little as 25% to 50% of the usual therapeutically active dose), thus decreasing or eliminating troublesome side effects while the combined effect on reducing intraocular pressure remains in the therapeutically useful range. | 2010-04-29 |
20100105644 | BOTANICAL COMPOSITION FOR ENHANCED SKIN REPAIR AND USES THEREOF - A skin augmentation composition comprises a therapeutically effective amount of a combination of a gingerol and a curcumin and a cosmetically or pharmaceutically acceptable carrier. Methods for enhancing the repair of damaged skin and the prevention of developing wounds in a subject having damaged skin comprises administering to a portion of damaged skin, a composition comprising a therapeutically effective amount of a combination of a gingerol and a curcumin and a cosmetically or pharmaceutically acceptable carrier. | 2010-04-29 |
20100105645 | INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS - This invention relates to methods for using agents to inhibit peroxisome proliferator activated receptor expression. | 2010-04-29 |
20100105646 | ALLOPREGNANOLONE IN A METHOD FOR ENHANCING NEUROLOGICAL FUNCTION (ALZHEIMER DISEASE) - Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and/or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning. | 2010-04-29 |
20100105647 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES - Disclosed is an amide compound represented by the following formula (1). (1) (In the formula, X | 2010-04-29 |
20100105648 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING (R)-(-)-2-[5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]CHROMAN - The invention relates to a solid pharmaceutical preparation containing (R)-(−)-2-[5-(4-fluorophenyl-3-pyridylmethylaminomethyl]chroman as an active substance and at least one sugar alcohol (e.g. mannitol, sorbitol) as a filler. Also disclosed is the production of said solid pharmaceutical preparation, which is provided with an increased shelf life also at elevated temperatures and can be used for the treatment of dyskinesia associated with Parkinson's disease. | 2010-04-29 |
20100105649 | VETERINARY COMPOSITIONS FOR TREATING MASTITIS - The present invention relates to a veterinary composition for the prophylaxis and treatment of mastitis in mammals, preferably cows. The formulations of the present invention comprise two parts that are optionally administered to the animal as a blended formulation or two separate formulations. The first part is a seal formulation comprising a gel base and a non-toxic heavy metal salt in the base. The second part of the formulation is an oil-based product preferably containing an antibiotic in an oil-based formulation. The oil-based formulation may also optionally contain any other pharmaceutically active agent for the treatment or prophylaxis of disease in cattle. | 2010-04-29 |
20100105650 | Substituted isoquinoline and isoquinolinone derivatives - The invention relates to 6-substituted isoquinoline and isochinolone derivatives of the formula (I) | 2010-04-29 |
20100105651 | ANTAGONISTS OF SNS SODIUM CHANNELS - Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents, formula (I): R | 2010-04-29 |
20100105652 | PURINES AS CYSTEINE PROTEASE INHIBITORS - Substituted heteroaryl nitrile salt of Formula I, | 2010-04-29 |
20100105653 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES - The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein. | 2010-04-29 |
20100105654 | SUBSTITUTED QUINAZOLINONE COMPOUNDS - A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structures VA, VB, VIIA and VIIB where the values of the variables are defined herein. | 2010-04-29 |
20100105655 | NOVEL COMPOUNDS 515 - There is provided novel pyrimidine derivatives of formula (I) | 2010-04-29 |
20100105656 | TRIAZOLOPYRAZINE DERIVATIVES - The invention relates to compounds of the formula I | 2010-04-29 |
20100105657 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease - The present invention relates to new compounds of formula (I), or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in the treatment of 5-HT6 mediated disorders such as Alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and Parkinson's disease. | 2010-04-29 |
20100105658 | AZA-BRIDGED-RING COMPOUND - [Problems] Provided is a compound which has an antagonistic action on a muscarinic M | 2010-04-29 |
20100105659 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS - Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase. | 2010-04-29 |
20100105660 | ORGANIC COMPOUNDS75074 - A compound of formula (I), or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M | 2010-04-29 |
20100105661 | CONDENSED PYRIDINE COMPOUND - The present invention provides a compound having excellent JAK3 inhibitory activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. | 2010-04-29 |
20100105662 | Besifloxacin Ophthalmic Composition for the Treatment or Control of Infection - A composition comprises besifloxacin in an amount effective for treating or controlling an infection caused by an antibiotic-resistant bacterium. Such a composition can be administered to a subject for the treatment or control of bacterial conjunctivitis caused bay an antibiotic-resistant bacterium. | 2010-04-29 |
20100105663 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS - The invention relates to substituted indazoles and methods for production thereof and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, especially of cardiovascular diseases, preferably of thromboembolic diseases. | 2010-04-29 |
20100105664 | ORGANIC COMPOUNDS - A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: | 2010-04-29 |
20100105665 | RENIN INHIBITORS - Compounds, pharmaceutical compositions, kits, article of manufacture, methods of using, and method of preparing of compounds having the formula of: | 2010-04-29 |
20100105666 | TRIAZABENZO (A)NAPHTHO(2,1,8-CDE) AZULENE COMPOUNDS. - Compounds of formula (I): | 2010-04-29 |
20100105667 | Quinoxaline- and Quinoline-Carboxamide Derivatives - The invention relates to compounds of formula (I) | 2010-04-29 |
20100105668 | Quinazoline derivatives - The present invention concerns the compounds of formula | 2010-04-29 |
20100105669 | PLANT HEALTH COMPOSITION - The present invention relates to a composition containing (A) at least one specific carbamate fungicide, (B) at least one specific insecticide and optionally (C) at least one azole, the use of this composition for improving plant health and a method for improving plant health by treating a plant, its propagules or the locus where the plant is growing or is to grow with the above composition. | 2010-04-29 |
20100105670 | FUNGICIDAL MIXTURES - Disclosed is a fungicidal mixture comprising (a) at least one compound selected from the compounds of Formula 1 N-oxides, and salts thereof, | 2010-04-29 |
20100105671 | C7-fluoro substituted tetracycline compounds - The present invention is directed to a compound represented by Structural Formula (A): | 2010-04-29 |
20100105673 | SUBSTITUTED AMINOFURANONES AND THEIR USE - The present invention relates to novel substituted aminofurans, to methods for their preparation, to their use in the treatment and/or prophylaxis of diseases as well as their use in the manufacture of medical products for the treatment and/or prophylaxis of diseases, in particular retroviral disorders, in humans and/or animals. | 2010-04-29 |
20100105674 | Chemical Compounds - The present invention relates to dianilinopyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such dianilinopyrimidine derivatives are useful in the treatment of diseases associated with inappropriate Wee1 kinase activity. | 2010-04-29 |
20100105675 | 11 BETA-HSD1 MODULATORS -
A compound according to Formula I:
| 2010-04-29 |
20100105676 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS - Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, [PLEASE INSERT CHEMICAL STRUCTURE HERE] (I) are useful as kinase modulators, including Btk modulation, wherein R1, R2, R4, Q, Y, A and D are as defined herein. | 2010-04-29 |
20100105677 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF - The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. | 2010-04-29 |
20100105678 | NOVEL ANXIOLYTIC COMPOUNDS - The present invention relates to chemical compounds of general formula (I) which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders. | 2010-04-29 |
20100105679 | 5-PYRIDINONE SUBSTITUTED INDAZOLES - Various 5-substituted 1-substituted indazoles are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described. | 2010-04-29 |
20100105680 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS - The present invention relates to substituted dimethylcyclobutyl compounds of general formula I, a process for their preparation, medicaments comprising said substituted dimethylcyclobutyl compounds as well as the use of said substituted dimethylcyclobutyl compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via sigma receptors. | 2010-04-29 |
20100105681 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS - The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2010-04-29 |
20100105682 | CYCLOPROPYL-PIPERAZINE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS - Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type calcium channel activity are disclosed. Specifically, a series of compounds containing both a piperazine ring and a cyclopropyl ring are disclosed of the general formula (I) where X | 2010-04-29 |
20100105683 | COMPOUNDS USEFUL FOR INHIBITING CHK1 - Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed. | 2010-04-29 |
20100105684 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention relates to heterocyclyl-substituted-tetrahydro-naphthalen-amine compounds of general formula (I) and compositions thereof, methods for their preparation, and the use of said compounds for the treatment or prophylaxis of various disorders of humans or animals. | 2010-04-29 |
20100105685 | S-Nitrosothiol Compounds and Related Derivatives - The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a single compound which treats lack of normal breathing. In another aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a combination of two or more compounds, at least one of which treats lack of normal breathing. In an aspect, a compound is an S-nitrosylating agent. | 2010-04-29 |
20100105686 | PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS - The present invention relates to new sulfonamide derivatives of formula (I) | 2010-04-29 |
20100105687 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS - Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of the following formula, Formula (2), wherein the variables have the meaning defined in the specification. | 2010-04-29 |
20100105688 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 - The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker, wherein at least one of them is at subtherapeutic dose, as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain. | 2010-04-29 |
20100105689 | NOVEL 1,4- AND 1,5-DIARYLSUBSTITUTED 1,2,3-TRIAZOLES USEFUL AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel 1,4- and 1,5-diarylsubstituted 1,2,3-triazole derivatives that are found to be potent modulators of potassium channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to modulation of potassium channels. | 2010-04-29 |
20100105690 | LISOFYLLINE ANALOGS AND METHODS FOR USE - Analogs of a Lisofylline (LSF), and synthetic methods for the preparation of such analogs are provided. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic β-cells. | 2010-04-29 |
20100105691 | METFORMIN FOLATE AND PREPARATION OF THE SAME - The present invention discloses a novel biguanidine compound, i.e. folacin-metformin, and its manufacture with inorganic salt of metformin as raw material. Compared with metformin, the compound has the same clinic curative effect, such as lowering blood sugar, curing poly-cystic ovary syndrome (PCOS), losing weight and so on, without resulting in the increase of homocysteine concentration, even with a little decrease of homocysteine concentration in some cases. | 2010-04-29 |
20100105692 | Dipterinyl Calcium Pentahydrate (DCP) and Therapeutic Methods Based Thereon - Provided herein is dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. Also provided herein is the compound dipterinyl calcium pentahydrate (DCP) or an analog or polymorph thereof. | 2010-04-29 |
20100105693 | Modulators of Muscarinic Receptors - The present invention relates to substituted piperazine compounds that are useful modulators of muscarinic receptors. The present invention also provides compositions comprising such compounds, and methods for treating muscarinic receptor mediated diseases. | 2010-04-29 |
20100105694 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE - The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in claim | 2010-04-29 |
20100105695 | METHOD FOR ENHANCING INSULIN SECRETION - The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or the R- or S-enantiomer of ranolazine for enhancing endogenous insulin levels in a patient in need thereof. It is also directed to a composition comprising an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine and at least one anti-diabetic agent. | 2010-04-29 |
20100105696 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS - The invention relates to the use of compounds of formula (I) | 2010-04-29 |
20100105697 | THERAPEUTIC AGENTS - The present invention is directed to therapeutic agents of the formula (I) which are atypical antipsychotics and which are useful in the treatment of neurological and psychiatric disorders associated with dopamine D2 and serotonin 5-HT2A neurotransmission dysfunction. wherein; R | 2010-04-29 |